期刊
BRITISH JOURNAL OF CANCER
卷 116, 期 5, 页码 649-657出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2017.2
关键词
necrosis; hypoxia; muscle invasive bladder cancer; radiotherapy; chemotherapy; randomised controlled trial; BC2001
类别
资金
- Cancer Research UK [C547/A2606, C547/A6845, C9764/A9904, C1491/A9895, C2094/A11365]
- Experimental Cancer Medicine Centre [C1467/A7286]
- Medical Research Council [G0801525] Funding Source: researchfish
- MRC [G0801525] Funding Source: UKRI
Background: Severe chronic hypoxia is associated with tumour necrosis. In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia modification of radiotherapy. Adding mitomycin C (MMC) and 5-fluorouracil (5-FU) chemotherapy to radiotherapy improved locoregional control (LRC) compared to radiotherapy alone in the BC2001 trial. We hypothesised that tumour necrosis would not predict benefit for the addition of MMC and 5-FU to radiotherapy, but would be prognostic. Methods: Diagnostic tumour samples were available from 230 BC2001 patients. Tumour necrosis was scored on whole-tissue sections as absent or present, and its predictive and prognostic significance explored using Cox proportional hazards models. Survival estimates were obtained by Kaplan-Meier methods. Results: Tumour necrosis was present in 88/230(38%) samples. Two-year LRC estimates were 71% (95% CI 61-79%) for the MMC/ 5-FU chemoradiotherapy group and 49% (95% CI 38-59%) for the radiotherapy alone group. When analysed by tumour necrosis status, the adjusted hazard ratios (HR) for MMC/ 5-FU vs. no chemotherapy were 0.46 (95% CI: 0.12-0.99; P=0.05, necrosis present) and 0.55 (95% CI: 0.31-0.98; P=0.04, necrosis absent). Multivariable analysis of prognosis for LRC by the presence vs. absence of necrosis yielded a HR=0.89 (95% CI 0.55-1.44, P=0.65). There was no significant association for necrosis as a predictive or prognostic factor with respect to overall survival. Conclusions: Tumour necrosis was neither predictive nor prognostic, and therefore MMC/5-FU is an appropriate radiotherapy-sensitising treatment in MIBC independent of necrosis status.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据